 Home > Medical News > Medical Science News > Novartis announces overall survival data for MET inhibitors

Novartis announces overall survival data for MET inhibitors

 Last Update: 2021-06-16
 Source: Internet
 Author: User

Tags

1 2 addition

small molecule

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Recently, at the American Society of Clinical Oncology in 2021, Novartis announced the latest phase 2 clinical trial data of the oral highly selective small molecule MET inhibitor Tabrecta in the treatment of adult patients with metastatic non-small cell lung cancer
.

These patients carry genetic mutations that cause the skipping of exon 14 of the MET gene

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Novartis announces overall survival data for MET inhibitors for first-line treatment of specific non-small cell lung cancer

06-16

Related Products

3-bromodibenzo[b,d]thiophene

CAS No.: 97511-04-1

$1/KG EXW

3-Iodo-9H-carbazole

CAS No.: 16807-13-9

$1/KG EXW

4-BroMo-9H-carbazole

CAS No.: 3652-89-9

$1/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

announcements today(81)

80 20 company(94)

united states logo(227)

single use technology(195)

healthy food name(42)

ups united states(221)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.

Novartis announces overall survival data for MET inhibitors

Related Articles

Novartis announces overall survival data for MET inhibitors for first-line treatment of specific non-small cell lung cancer